To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
December 21, 2005
William R. Sellers, MD (Damon Runyon Clinical Investigator '01-'05) reported that a new class of drugs called MEK inhibitors selectively suppresses growth of cancer cells and tumors that harbor a mutation in the BRAF gene. BRAF is a protein that acts as a critical regulator of cellular growth, differentiation, and survival.